Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Benitec Biopharma Ltd. ($BNTC) provided update about its Investigational New Drug application in the US for its gene therapy BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD). The company plans to file the IND application in the fourth quarter of 2018. Benitec plans to commence an initial study in the humans shortly. The update has given a positive impetus to the stock, which climbed 6 percent in its previous trading session.

The stock has gained 92 percent this year so far while its 12 months gain stands at 89 percent.

<p align="left">

</p>

Protalix BioTherapeutics ($PLX) announced positive results from a Phase 1/2 open-label extension study assessing PRX-102 in patients with Fabry Disease. The trial results at month 24 showed sustained responses across all key Fabry parameters, including a 90% decrease from baseline in Lyso Gb3 levels, stable renal and cardiac function and a 40% improvement in disease severity.

The stock gained over 2 percent in its previous trading session. It is up 64 percent this year so far while its 12 months gain stands at 43 percent.

<p align="left"><span style="line-height: 1.5;">

</span></p>
&nbsp;

Biohaven Pharmaceuticals ($BVHN) announced that it has hit the enrollment target for its second Phase 3 clinical trial, BHV3000-302, assessing rimegepant for the acute treatment of migraine. The company expects the top line data from '302 and the first Phase 3, BHV3000-301, to be available next quarter.

Titan Pharmaceuticals ($TTNP) announced that the European Medicines Agency accepted for review the marketing application seeking approval for Probuphine (buprenorphine) for the treatment of opioid dependence. The FDA approved Probuphine, a subdermal implant that delivers buprenorphine for six months, in May 2016.

 

Dova Pharmaceuticals ($DOVA) reported that the FDA has accepted for review its marketing application seeking the approval for avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease about to undergo a procedure. The drug candidate has Priority Review status and the agency’s action date is set at May 21, 2018.

Apollo Endosurgery ($APEN) announced that its OverStich Sx has been granted 510(k) clearance. The product is a full-thickness flexible endoscopic suturing system that can be used with a much broader range of single-channel flexible endoscopes than the current version. The company plans to launch the product in the US and Europe in the first half of 2018.

<p align="left">

&nbsp;

Corbus Pharmaceuticals ($CRBP) announced that it has been issued the US Patent Nom 9,820,964 by the USPTO. The patent covers the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including systemic sclerosis, dermatomyositis and cystic fibrosis. The patent is in effect through 2034.

Express Scripts ($ESRX) signed an agreement to sell its subsidiary United BioSource to private equity outfit Avista Capital Partners. The parties did not disclose the financial terms of the agreement.

<p align="left">

 

</p>

Brokerage CompanyBrokerage CompanyName Rating PriceTarget Impact onShare Price ActionsPiper Jaffray CompaniesAcorda Therapeutics (ACOR)Hold $22.00 Low       HC WainwrightCheck-Cap (CHEK)Buy $7.00 -> $5.50 Low       Jefferies GroupDova Pharmaceuticals (DOVA)Buy $33.00 Low       HC WainwrightGalectin Therapeutics (GALT)Buy $3.50 -> $6.00 Low       StephensHenry Schein (HSIC)Equal Weight Low
<p align="left">

</span></p>

Gainers (% price change)Last TradeChangeMkt CapLife Technologies Corp4.35+0.35 (8.75%)129.45MTeva PharmaceuticalTEVA14.65+1.02 (7.50%)15.43BFluidigm CorporationFLDM6.11+0.35 (6.08%)236.14MInsys Therapeutics IncINSY5.33+0.28 (5.54%)390.78MAceto CorporationACET10.73+0.54 (5.30%)328.78MLosers (% price change)Quidel CorporationQDEL36.33-3.58 (-8.97%)1.24BCompugen Ltd. (USA)CGEN2.58-0.22 (-8.04%)120.35MTaro PharmaceuticalTARO108.36-7.09 (-6.14%)4.39BNova MeasuringNVMI29.55-1.83 (-5.83%)762.39MOmeros CorporationOMER18.20-0.98 (-5.11%)873.67MMost Actives (dollar volume)UnitedHealth Group IncUNH212.40-0.11 (-0.05%)205.36BTeva PharmaceuticalTEVA14.65+1.02 (7.50%)15.43BMerck & Co., Inc.MRK54.55+0.20 (0.37%)148.78BJohnson & JohnsonJNJ138.10+0.93 (0.68%)371.01BCelgene CorporationCELG103.33-1.17 (-1.12%)81.35B

<p align="left">

</p>